Leesburg, VA, July 9, 2020--An open-access American Journal of Roentgenology (AJR) article investigating the differences in CT findings between coronavirus disease (COVID-19) pneumonia and influenza virus pneumonia found that most lesions from COVID-19 were located in the peripheral zone and close to the pleura, whereas influenza virus was more prone to show mucoid impaction and pleural effusion.

"However," lead author Liaoyi Lin of China's First Affiliated Hospital of Wenzhou Medical University cautioned, "differentiating between COVID-19 pneumonia and influenza virus pneumonia in clinical practice remains difficult."

A total of 97 patients (49 women, 48 men) were enrolled in this study. Of them, 52 patients (29 men, 23 women; age range, 21-73 years) had COVID-19 pneumonia; 45 patients (26 women, 19 men; age range, 15-76 years) had influenza virus pneumonia (28, influenza A; 17, influenza B). All patients had positive nucleic acid testing results for the respective viruses, as well as complete clinical data and CT images.

According to Lin and colleagues: "Between the group of patients with COVID-19 pneumonia and the group of patients with influenza virus pneumonia, the largest lesion close to the pleura (i.e., no pulmonary parenchyma between the lesion and the pleura), mucoid impaction, presence of pleural effusion, and axial distribution showed statistical difference (p < 0.05)."

Meanwhile, Lin et al. noted that the properties of the largest lesion, presence of ground-glass opacities, consolidation, mosaic attenuation, bronchial wall thickening, centrilobular nodules, interlobular septal thickening, crazy paving pattern, air bronchogram, unilateral or bilateral distribution, and longitudinal distribution did not show significant differences (p > 0.05).

Additionally, the authors observed no significant difference (p > 0.05) in CT score, length of the largest lesion, mean density, volume, or mass of the lesions between the two groups.

Because the CT manifestations of COVID-19 and influenza virus so often overlap, "even with the characteristics evaluated using AI software," Lin et al. wrote, "no significant differences were detected."

Thus, the authors of this AJR article concluded that the more important role of CT during the present pandemic is in finding lesions and evaluating the effects of treatment.

ISSN: 2155-9899
Journal Impact Factor: 2.3*
NLM title abbreviation: J Clin Cell Immunol
NLM ID: 101563152
ICV: 82.55
DOI: 10.35248/2155-9899
Publication policy: Open Access
Contact email: immunology@eclinicalsci.com

Journal of Clinical and Cellular Immunology is a leading open access journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology.

Editor-in-Chief Charles J Malemud is supported by an outstanding Editorial Board of international researchers.

This peer reviewed journal includes clinical and cellular Immunological aspects such as Systemic Lupus Erythmatosus, Cancer Immunology, Tumor Biology, Macrophage Polarization, Transplantation Immunology, Innate Immunology, Adaptive Immunity, Cellular & Molecular Immunology, Vaccine Development, Signal Transduction, Innate Immunity, Cancer Immunotherapy, Inflammatory Disorders, Medical Immunology, Diagnostic Immunology, Clinical Immunology, HIV Immunology, Allergy & Immunology, Immunomodulation, Multiple Sclerosis, Neuroinflammatory Diseases, Clinical & Vaccine Immunology, Clinical Experimental Immunology, T-cell Immunology etc.

This Science Journal publishes research articles, reviews, case studies, commentaries, short communications, and letters to the editor on various aspects of Cellular and Clinical Immunology making them freely available worldwide. To attain high impact factor, quality articles are expected from all over the world for this open access and peer reviewed front running journal.

JCCI is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking systems used by most of the best open access journals. Review processing is performed by the editorial board members of Journal of Clinical & Cellular Immunology or outside experts; at least two independent reviewers approval followed by editor's approval is required for acceptance of any citable manuscript. Annual reviews of Immunology Journal is also shared with authors.

Authors can submit manuscripts online at Editorial Tracking System (https://www.longdom.org/submissions/clinical-cellular-immunology.html) or forwarded to the Editorial Office at: immunology@eclinicalsci.com (or) jcci@peerreviewedjournals.com

Benefits of Publication with us:

• Fast track Peer-review process in 21 days.
• Publication immediately after acceptance.
• Peer-review by international experts.
• Enhanced visibility for the published articles through digital media & Open-Access.

Media Contact:
Mercy Eleanor | Managing Editor
Journal of Clinical & Cellular Immunology
Whatsapp No:  +1-504-608-2390
Email: immunology@eclinicalsci.com